S
Saladax Biomedical
Commercial-stage therapeutics developer with an initial focus on oncology
About Saladax Biomedical
Saladax Biomedical specializes in developing rapid blood tests aimed at enhancing personalized medicine for psychiatrists, oncologists, and neurologists. Operating in the healthcare diagnostics market, Saladax provides laboratories worldwide with innovative diagnostic solutions that ensure reliable and swift diagnosis. The company’s business model revolves around creating and supplying high-quality assays that enable personalized dosing, ensuring that the right drug is administered at the right dose for each unique patient. By focusing on the areas of Psychiatry, Oncology, and Neurology, Saladax addresses the critical need for precision medicine, thereby improving patient outcomes and healthcare efficiency. Revenue is generated through the sale of these diagnostic tests to laboratories and healthcare providers globally.
Source: Dealroom company dataAt a glance
- Founded
- 2004
- Headquarters
- Bethlehem, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Ben Franklin Technology Partners of Northeastern Pennsylvania
Series A3 investors entered at this stage
Columbia Ventures Corporation
Pittsburgh Life Sciences Greenhouse
Grape Arbor VC
Series B and later4 investors entered at this stage
Excel Venture Management
Golden Seeds
GE Capital
Shanghai Electric Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Saladax Biomedical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Saladax Biomedical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.